How we can fix biopharma’s broken and battered image was the topic of a panel of seven biopharma executives convened this year by Life Science Leader at the JPM Conference in San Francisco.
Garo Armen, CEO of Agenus and a long-time pharma industry veteran, has shown the instincts for simple money-making on one hand and the humanitarian side of biopharma on the other.
Deborah Waterhouse discusses her journey toward becoming CEO of ViiV Healthcare, an HIV joint venture between GSK, Pfizer and Shionogi, and her focus as a leader around innovation, building the “trust agenda” and company performance.
What makes a successful merger? Here we look at the 2018 merger between genome-therapy-focused company Sangamo Therapeutics and TxCell, which focuses on regulatory T-cell (Treg) development for immunological diseases.
Tim Scott, founder and CEO at both a CDMO and start-up biotech, maps out financial understanding for leaders of both approaches.
A retired pharma executive decides to tackle the daunting task of revamping the U.S. healthcare system.
The story of how John Leonard found his “next adventure” in pharma as president and CEO of Intellia Therapeutics — and what he’s doing to capitalize on it.
Joaquin Duato, vice chairman of J&J’s executive committee, discusses how the company’s partnering and innovation-building model has evolved — and why.
Outsourced Pharma Chief Editor Louis Garguilo continues his coverage of the current state of China pharma manufacturing by interviewing Diana Francis, VP of quality and compliance for BeiGene.
“A partnering deal with a bigger pharma company would certainly help us through [the Phase 3] process,” explains Jeff Davidson, CEO of Keystone Nano, a company that develops nanoparticles that target solid tumors by going after cancer cells and leaving the normal cells intact.
“Making sure we had the money for staff and activities to build the business for the long-term was a key initial step,” explains Dr. Helen Torley, CEO of Halozyme Therapeutics.
An in-depth look at three developers that exemplify the range of new approaches and alternatives in the IO combo space: Oncosec Medical, Heat Biologics, and Rexahn.
We connected with a collection of biopharma financial experts to get you prepared for JPM, BTS, and the BIO CEO & Investors Conference in the first quarter of 2019.
Industry experts answer questions around future biopharma manufacturing trends, challenges, technologies, performance metrics, risk mitigation, people, and outsourcing.
You might know Richard Pops is one of the longest tenured CEOs in biopharma, but here are six things perhaps you didn’t know about the chairman of Alkermes.
Rachel King, CEO and cofounder of GlycoMimetics, talks about women in the biopharma industry as part of this preview of her feature story that appears in the May issue of LSL.
Richard Pops, CEO of Alkermes, discusses his philosophy of being forward looking, but shares how such an approach can also have its drawbacks.
The Conference Forum’s invitation only R&D Leadership Summit sheds light on areas of focus and concern for top biopharmaceutical industry executives.
The Netherlands’ biopharma press tour concludes in Amsterdam with presentations (e.g., AIMM Therapeutics) and guided tours of the O2 building and the National Screening Laboratory (NSS) for Sanquin.
